DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report published on Friday. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $10.00 price target on shares of DBV Technologies in a report on Wednesday, February 21st.

DBV Technologies Price Performance

DBVT opened at $0.69 on Friday. The stock has a market capitalization of $133.95 million, a PE ratio of -1.78 and a beta of 0.75. The firm’s fifty day moving average price is $0.81 and its 200 day moving average price is $0.90. DBV Technologies has a 12-month low of $0.65 and a 12-month high of $2.37.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.10. The firm had revenue of $8.88 million for the quarter, compared to analysts’ expectations of $1.10 million. DBV Technologies had a negative net margin of 461.32% and a negative return on equity of 46.33%. During the same period in the prior year, the company posted ($0.23) earnings per share. On average, equities research analysts forecast that DBV Technologies will post -0.88 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A number of institutional investors and hedge funds have recently modified their holdings of DBVT. BlackRock Inc. raised its holdings in shares of DBV Technologies by 16.5% during the first quarter. BlackRock Inc. now owns 687,341 shares of the company’s stock worth $1,093,000 after purchasing an additional 97,412 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in shares of DBV Technologies during the second quarter worth $49,000. ExodusPoint Capital Management LP acquired a new stake in shares of DBV Technologies during the second quarter worth $352,000. Envestnet Asset Management Inc. bought a new position in shares of DBV Technologies during the third quarter worth about $67,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of DBV Technologies during the third quarter worth about $26,000. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.